← Back to patent-cliff list
GUB-014295
Tier C — Watch / tradeGUB-014295
Gubra A/S
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Amylin Receptor, Adrenomedullin receptor
Indications (approved)：Overweight, Obesity
Regional status
US
Phase II
2026-08-04
EU
Phase I
2023-11-29
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of GUB-014295?
Approved indications include: Overweight, Obesity.
When does the GUB-014295 patent expire?
No public expiry year is available for GUB-014295 yet; this page updates once verified.
How do I get a quote for GUB-014295 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29